September 11, 2019 8:29am
The ebb and flow of market sentiment should overflow to “our’ universe of cell and gene therapy companies
Indexes and ETFs can’t “always” define the cause and effect of relationship between the key factors that explain pricing’s direction
My version of the morning’s numbers is written to be informative than just about changes to fundamentals; it’s what happened or will beyond the headline and what could happen to the future
We should all observe (along with the NYSE) a minute of silence to honor the 9/11 terror attack victims and their families as well as the survivors and first-responders
Timely insights have line extensions within or to a volatile pricing universe. Thus my line in writing is separating actionable numbers or intelligence and news into a short-term investment thesis to tackle the “unknown unknowns”
Dow futures are UP +0.17% (+47 points), S&P futures are UP +0.17% (+5 points) and NASDAQ futures are UP +0.25% (+20 points)
Stock futures are higher and still fluctuating as Wednesday’s session looms ahead of inflation data’s release;
European stocks are higher ahead of the central bank (ECB) meetings;
Asia Pacific stocks are mixed awaiting ECB interest rate decisions.
Data docket: PPI data due at 8:30 a.m. ET and wholesale trade figures out at 10:00 a.m. ET.
The Dow is currently on a five-day win streak, it’s longest since early June, but the NASDAQ is riding a three-day losing streak. The S&P 500 has been up in four of the past five days, but has moved less than a point in each of the past two sessions. All this comes before policy-setting meetings at the European Central Bank tomorrow and the Fed next week. (CNBC)
Today’s market focus is on economic indicators and trade relations between China and the U.S. after Beijing released a tariff exemptions list for products from the U.S. on Wednesday morning.
China's Ministry of Finance today announced plans to exempt 16 types of U.S. goods from additional tariffs, including food for livestock, cancer drugs and lubricants. The exemption, which is scheduled to go into effect from Sept. 17, will be valid for a year and comes as high-level trade officials from the two countries prepare to meet next month. (CNBC)
Which could be a good thing as each country tries to find the boundaries of a possible resolution to their “saving face” in their negotiations, I believe!
I keep reminding myself that fact and fiction tend to merge as time moves forward
From Tuesday’s evening post, “get nervous after two (2) up sector sessions. I’m thankful of appreciation of the past oversold “conditions” but, value’s performance seems lately to be “pierced” by short-term profit taking.”
• The NASDAQ was down -3.28 or -0.04% to 8,084.15;
• The IBB closed up +1.15% while the XBI also closed up +2.47% after Monday’s IBB closed down -0.41% while the XBI also closed down -0.15%;
• The close was positive with an A/D Line of 31/10 and 2 flats and 2 acquired;
• The range of the 31 upside was +0.26% (BLFS) to +20.87% (MESO) while the 10 downside ranged from -0.44% (STML) to -11.66% (HSGX);
• 9 out of the 31 upside had higher than the 3 month average volume;
• 7 out of the 10 downside had higher than the 3 month average volume;
Q3/19 to date:
- In July, there were 9 positive, 1 holiday and 13 negative closes;
- In August there had been 12 negative and 10 positive closes
- In September there has been 4 positive, 1 holiday and 2 negative close
Companies in my headlights – It’s your decision; I provide an idea and context:
*** Stay steady on the sidelines as to the outcomes of electronic trading and algorithmic “rules” in today’s market - How many times has ... strength been sold into ...?***
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.